← All organizations
Highest phase reached
Phase 3
First clinical trial
Nov 2, 1999First marketed drug
Nov 22, 2002First NDA
Nov 22, 2002Last known activity
Jan 31, 2022
Timeline
1890s
- Jan 1, 1896
Romark— Founded
2000s
- Nov 22, 2002
nitazoxanide— NDA Organization
Drugs by trial phase (7 distinct, 29 trials)
Phase 3 (6 own, 0 via acquisition)
Phase 2 (1 own, 0 via acquisition)
Indications
Studied for
- Adenoviridae Infections
- Amebiasis
- Caliciviridae Infections
- Clostridium Infections
- Colitis
- Communicable Diseases
- Crohn Disease
- Cryptosporidiosis
- Diarrhea
- Dysentery, Amebic
- Enterovirus Infections
- Gastroenteritis
- Hepatitis
- Hepatitis A
- Hepatitis B
- Hepatitis B, Chronic
- Hepatitis C
- Hepatitis C, Chronic
- Hepatitis, Chronic
- Infections
- Influenza, Human
- Rotavirus Infections
Marketed drugs (1)
Recent trials (37)
- NCT05157269Lead sponsorPhase 3Jan 31, 2022
- NCT05157243Lead sponsorPhase 3Jan 31, 2022
- NCT04486313Lead sponsorPhase 3Aug 13, 2020
- NCT04489381Lead sponsorPhase 3Aug 13, 2020
- NCT04343248Lead sponsorPhase 3Apr 30, 2020
- NCT04359680Lead sponsorPhase 3Apr 30, 2020
- NCT03905655Lead sponsorPhase 2Jun 1, 2019
- NCT03605862Lead sponsorPhase 3Sep 11, 2018
- NCT03605862Study directorPhase 3Sep 11, 2018
- NCT03336619Lead sponsorPhase 3Jan 17, 2018
- NCT03336619Study directorPhase 3Jan 17, 2018
- NCT02612922Lead sponsorPhase 3Dec 1, 2015
- NCT02612922Study directorPhase 3Dec 1, 2015
- NCT01610245Study directorPhase 3Mar 1, 2013
- NCT01610245Lead sponsorPhase 3Mar 1, 2013
Details
- Founded
- Tampa, FL, US Jan 1, 1896
- First NDA
- Nov 22, 2002
- Last known activity
- Jan 31, 2022
Designations held
- Orphan drug
- Priority review